Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDFT1 | P37268 | 2/20 | 0.57 |
| ▸ | MDM4 | O15151 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.55 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.54 |
| ▸ | CASP3 | P42574 | 2/20 | 0.53 |
| ▸ | TLR2 | O60603 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29768618 | 1.00 | FDFT1 (0.57) | FDFT1MDM4TP53MDM2CASP3 | |
| SCHEMBL4600701 | 1.00 | FDFT1 (0.57) | FDFT1MDM4TP53MDM2CASP3 | |
| SCHEMBL29762010 | 1.00 | FDFT1 (0.57) | FDFT1MDM4TP53MDM2CASP3 | |
| SCHEMBL800035 | 1.00 | FDFT1 (0.57) | FDFT1MDM4TP53MDM2CASP3 | |
| SCHEMBL800305 | 1.00 | FDFT1 (0.57) | FDFT1MDM4TP53MDM2CASP3 | |
| SCHEMBL29362132 | 1.00 | FDFT1 (0.57) | FDFT1MDM4TP53MDM2CASP3 | |
| Sulfur Dioxide SCHEMBL29187399 | 0.98 | FDFT1 (0.56) | FDFT1MDM4TP53MDM2CASP3 | |
| SCHEMBL30437543 | 0.93 | MDM2 (0.57) | FDFT1MDM4TP53MDM2CASP3 | |
| SCHEMBL9062110 | 0.92 | MDM4 (0.58) | MDM4TP53MDM2CASP3TLR2 | |
| SCHEMBL9062116 | 0.92 | MDM4 (0.58) | MDM4TP53MDM2CASP3TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4602368-A1 | NITRILOTRIACETIC ACID LINKERS, SOLID PHASE SYNTHESIS OF NITRILOTRIACETIC ACID LINKERS AND APPLICATIONS THEREOF | Nicoya Lifesciences Inc. (CA) | 2025-08-20 | — | — | EP | claimed |
| WO-2024077385-A9 | NITRILOTRIACETIC ACID LINKERS, SOLID PHASE SYNTHESIS OF NITRILOTRIACETIC ACID LINKERS AND APPLICATIONS THEREOF | Nicoya Lifesciences Inc. (CA) | 2024-06-20 | — | — | WO | claimed |
| WO-2024077385-A1 | NITRILOTRIACETIC ACID LINKERS, SOLID PHASE SYNTHESIS OF NITRILOTRIACETIC ACID LINKERS AND APPLICATIONS THEREOF | Nicoya Lifesciences Inc. (CA) | 2024-04-18 | — | — | WO | claimed |
| CN-119978070-B | Cyclohexapeptide for skin care, and composition and application thereof | 深圳市维琪科技股份有限公司 | 2026-05-19 | — | — | CN | disclosed |
| US-20260124313-A1 | SITE-SPECIFIC COVALENT LIGATION OF HUMAN SERUM ALBUMIN | UNIV CALIFORNIA (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4602368-A1 | NITRILOTRIACETIC ACID LINKERS, SOLID PHASE SYNTHESIS OF NITRILOTRIACETIC ACID LINKERS AND APPLICATIONS THEREOF | Nicoya Lifesciences Inc. (CA) | 2025-08-20 | — | — | EP | disclosed |
| US-20250231184-A1 | NITRILOTRIACETIC ACID LINKERS, SOLID PHASE SYNTHESIS OF NITRILOTRIACETIC ACID LINKERS AND APPLICATIONS THEREOF | SWK FUNDING LLC | 2025-07-17 | — | — | US | disclosed |
| WO-2025124099-A1 | PREPARATION METHOD FOR AND USE OF MOLYBDENUM-SULFIDE-BASED CATALYST | 中国科学院大连化学物理研究所 | 2025-06-19 | — | — | WO | disclosed |
| CN-120155194-A | Preparation method and application of molybdenum sulfide-based catalyst | 中国科学院大连化学物理研究所 | 2025-06-17 | — | — | CN | disclosed |
| CN-119978070-A | Cyclohexapeptide for skin care, and composition and application thereof | 深圳市维琪科技股份有限公司 | 2025-05-13 | — | — | CN | disclosed |
| EP-4217007-B9 | PEPTIDIC CONJUGATES OF SN38 USEFUL IN THE TREATMENT OF CANCER | FUNDACIO INST DE RECERCA BIOMEDICA IRB BARCELONA (ES) | 2025-01-15 | — | — | EP | disclosed |
| WO-2023028008-A2 | COMBINATION OF RELAXIN AND VASOPRESSIN ANALOGUES FOR TREATMENT OF RENAL DISORDERS OR CONDITIONS | RIVER 2 RENAL CORP. (US) | 2023-03-02 | — | — | WO | disclosed |
| CN-110194785-B | Multi-target peptide molecule of opioid and neuropeptide FF receptor and preparation and application thereof | 上海天慈生命科学发展有限公司 | 2023-02-24 | — | — | CN | disclosed |
| CN-110183514-B | Multi-target peptide molecules of opioid and neuropeptide FF receptors and preparation and application thereof | 上海天慈生命科学发展有限公司 | 2022-12-30 | — | — | CN | disclosed |
| US-20220411390-A1 | MODULATION OF BACTERIAL QUORUM SENSING WITH SYNTHETIC LIGANDS | WISCONSIN ALUMNI RES FOUND (US) | 2022-12-29 | — | — | US | disclosed |
| EP-4093401-A1 | SALICYLAMIDE DERIVATIVES AND RELATED METHODS OF MAKING | The Board of Regents of the University of Texas System (US) | 2022-11-30 | — | — | EP | disclosed |
| US-20220283131-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS CO., LTD. (KR) | 2022-09-08 | — | — | US | disclosed |
| CN-112500457-B | Dual-targeting FOXM1/CDK1 anti-tumor polypeptide | 长沙新生康源生物医药有限公司 | 2022-06-17 | — | — | CN | disclosed |
| WO-2022064052-A1 | PEPTIDIC CONJUGATES OF SN38 USEFUL IN THE TREATMENT OF CANCER | FUNDACIÓ INSTITUT DE RECERCA BIOMÈDICA (IRB BARCELONA) (ES) | 2022-03-31 | — | — | WO | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411390-A1 | MODULATION OF BACTERIAL QUORUM SENSING WITH SYNTHETIC LIGANDS | AHCYL1, EBPL, AIP | FDFT1 209/4885MDM4 1016/4885TP53 3185/4885 |
| US-20260124313-A1 | SITE-SPECIFIC COVALENT LIGATION OF HUMAN SERUM ALBUMIN | GLP1R, ALB, GIPR | FDFT1 4330/4885MDM4 4874/4885TP53 2182/4885 |
| US-20250231184-A1 | NITRILOTRIACETIC ACID LINKERS, SOLID PHASE SYNTHESIS OF NITRILOTRIACETIC ACID LINKERS AND APPLICATIONS THEREOF | SPR, NAPA, TST | FDFT1 4252/4885MDM4 3385/4885TP53 1475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.